FDA GMP Plan Stresses Consistency; Systems Approach Ratified By Crawford
This article was originally published in The Tan Sheet
Executive Summary
FDA will work with an outside consultant to help increase the consistency of pre-approval and post-approval manufacturing oversight
You may also be interested in...
Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei
GMP Dispute Resolution Pilot Proposed To Evaluate Three-Stage Process
An FDA dispute resolution 12-month pilot will evaluate a proposed three-level process to resolve disagreements involving "technical and scientific" disputes that arise as a result of drug good manufacturing practice inspections
OTC, Rx Drug Risk Equation May Be Altered In Upcoming GMP Plan
FDA is considering applying different levels of scrutiny to OTC and Rx drugs as part of its new risk-based approach to pharmaceutical Good Manufacturing Practices